Patient-reported impact of chronic urticaria compared with psoriasis in theUnited States

Abstract

Purpose: Data are lacking on the burden of chronic idiopathic urticaria (CIU) versus other dermatologic conditions. This analysis compared the burden of chronic urticaria (CU, proxy for CIU) with psoriasis.

Methods: Data from CU (N = 747) and psoriasis patients (N = 5107) came from 2010 to 2012 US National Health and Wellness Surveys. Outcomes included SF-12v2/SF-36v2 mental and physical component summary scores (MCS and PCS, respectively) and other health/activity-related measures.

Results: MCS score was 44.7 for CU, and 48.2, 44.7 and 44.3 for mild/moderate/severe psoriasis, respectively (US norm = 50). PCS score was 43.8 for CU, and 46.5, 44.1 and 40.3 for mild/moderate/severe psoriasis. Health utility score was 0.67 for CU, and 0.72, 0.67 and 0.65 for mild/moderate/severe psoriasis. More CU patients reported depression (39%), anxiety (42%) and sleep difficulties (50%) than psoriasis patients (any severity). Overall work impairment was 29% for CU, and 19%, 26% and 31% for mild/moderate/severe psoriasis. Activities impairment was 39% for CU, and 28%, 37% and 43% for mild/moderate/severe psoriasis. CU and psoriasis patients had frequent healthcare visits.

Conclusions: Patients with CU had impaired mental/physical health and work/non-work activities, similar to moderate-to-severe psoriasis patients. Results suggest that better disease management of CU is needed. This analysis should also reflect the significant burden of CIU.

Keywords:

• Chronic hives
• skin disorders
• burden
• health-related quality of life

Acknowledgements

This study was funded by Novartis Pharmaceutical Corporation and Genentech, Inc. Prakash Navaratnam and Howard Friedman of DataMed Solutions, LLC, provided statistical and analytical assistance for the project, and reviewed the manuscript. This assistance was funded by Novartis Pharmaceuticals Corporation and Genentech, Inc. Medical writing and editorial assistance was provided by Erin P. Scott, PhD of Scott Medical Communications, LLC. This assistance was funded by Novartis Pharmaceuticals Corporation and Genentech, Inc.

Disclosure statement

Susan Gabriel, Meryl H. Mendelson and Haijun Tian are employees of Novartis Pharmaceutical Corporation. Jonathan A. Bernstein is a primary investigator for Novartis and Genentech, Dyax, Shire, CSL Behring and Biocryst, is a speaker for Novartis and Genentech, Dyax, Shire, Greer, Baxalta and CSL Behring, and is a consultant for Dyax, Shire and CSL Behring. Maria-Magdalena Balp is an employee of Novartis Pharma AG. Jeffrey Vietri is an employee of Kantar Health, which received fees from Novartis for data access and analysis. Mark Lebwohl is an employee of the Mount Sinai Medical Center which receives research funds from AbGenomics, Amgen, Anacor, Boehringer Ingleheim, Celgene, Ferndale, Lilly, Janssen Biotech, Kadmon, LEO Pharmaceuticals, Medimmune, Novartis, Pfizer, Sun Pharmaceuticals and Valeant.